February 10, 2022: NCHR president Dr. Diana Zuckerman testifies to the FDA Advisory Committee on Oncologic Drugs on Sintilimab.
Read More »Author: Caroline Bradford
Biden’s ‘Cancer Moonshot’ Turns Toward Pollution
E&E News, February 3, 2022: President Biden made an emotional pledge to “end cancer as we know it” by reinvigorating the Cancer Moonshot Initiative he first launched in 2016, just one year after his son Beau succumbed to the disease. But experts, including us, point out that there isn’t enough focus on environmental causes of cancer.
Read More »What’s Wrong with the FDA?
Washington Monthly, January 20, 2022: If Robert Califf, the White House nominee for commissioner of the FDA, is confirmed by the Senate, he’ll take the reins of an agency with its reputation in tatters. Once revered as the global leader in drug regulation, the FDA has approved one bad drug and medical device after another over the past 30 years, leaving staff demoralized and overseas regulators scratching their heads. NCHR and other experts provide recommendations for improvements.
Read More »Biogen Alzheimer’s Drug Coverage Threatens Minorities’ Access
Bloomberg Law, January 13, 2022: Minority groups could have a harder time accessing Aduhelm, Biogen Inc.’s Alzheimer’s drug, under Medicare’s preliminary decision to limit coverage to patients enrolled in clinical trials, policy analysts say. But we explain that it will ensure that patients understand that the drug is experimental, with proven risks but no proven benefits.
Read More »Statement of Dr. Diana Zuckerman Regarding the January 11, 2022 CMS Decision about Aduhelm
January 11, 2022: Dr. Diana Zuckerman, president of NCHR, speaks in favor of CMS decision to limit coverage of the Alzheimer’s drug, Aduhelm.
Read More »